Contract Research & Services
Clinical Trials
Search Results: Clinical Trials
1-15 of 5251 results
Novo Nordisk’s semaglutide succeeds in two phase 3a type 2 diabetes trials
By PBR Staff Writer
Novo Nordisk said that oral semaglutide succeeded in two phase 3a trials by registering statistically significantly greater reductions in HbA1c and weight in adults with type 2 diabetes.
Contract Research & Services > Clinical Trials > News
Can-Fite delays phase 2 trial of liver cancer drug Namodenoson
By PBR Staff Writer
Israeli biotechnology company Can-Fite BioPharma revealed that the results of its phase 2 trial of its liver cancer drug Namodenoson (CF102) will be delayed longer than originally estimated.
Contract Research & Services > Clinical Trials > News
X4P-001-RD demonstrates promising activity in WHIM syndrome patients
By PBR Staff Writer
X4 Pharmaceuticals said that its X4P-001-RD has demonstrated promising activity in the ongoing open-label phase 2 portion of a phase 2/3 study in patients with WHIM syndrome.
Contract Research & Services > Clinical Trials > News
BMS’ elotuzumab / pomalidomide improves progression-free survival in cancer trial
Bristol-Myers Squibb (BMS) has announced that the ELOQUENT-3 trial, an international Phase 2 study evaluating the addition of Empliciti (elotuzumab) to pomalidomide and low-dose dexamethasone (EPd) in patients with relapsed/refractory multiple myeloma (RRMM), achieved its primary endpoint.
Contract Research & Services > Clinical Trials > News
Futility forces Teva to halt fremanezumab’s chronic cluster headache study
By PBR Staff Writer
Israel-based Teva Pharmaceutical Industries said that it will stop an ongoing phase 3 trial of its migraine drug fremanezumab for the treatment of chronic cluster headache due to futility.
Contract Research & Services > Clinical Trials > News
Faron Pharmaceuticals reports inconsistent Traumakine biomarker results
Faron Pharmaceuticals has announced preliminary biomarker data from its Phase III INTEREST trial of Traumakine for the treatment of Acute Respiratory Distress Syndrome (ARDS).
Contract Research & Services > Clinical Trials > News
ViiV’s dolutegravir/lamivudine regimen succeeds in two phase 3 HIV-1 trials
By PBR Staff Writer
ViiV Healthcare reported that two phase 3 trials evaluating the two-drug regimen (2DR) of dolutegravir (Tivicay) and lamivudine (Epivir) in treatment naïve HIV-1 infected adults demonstrated the ability to control HIV.
Contract Research & Services > Clinical Trials > News
Flex Pharma to stop two neuromuscular disease trials over safety concerns
By PBR Staff Writer
Flex Pharma said that it is scrapping two ongoing phase 2 neuromuscular disease trials, evaluating its lead drug candidate FLX-787, due to safety concerns.
Contract Research & Services > Clinical Trials > News
Grünenthal begins phase III trials in Complex Regional Pain Syndrome
Grünenthal has recruited first patients in two trials of pivotal phase III program to investigate neridronate for the treatment of Complex Regional Pain Syndrome (CRPS).
Contract Research & Services > Clinical Trials > News
AstraZeneca, Eli Lilly terminate clinical trials of Alzheimer's disease treatment lanabecestat
By PBR Staff Writer
AstraZeneca and Eli Lilly have announced the termination of global phase 3 clinical trials of Alzheimer's disease treatment, lanabecestat, which is an oral beta secretase cleaving enzyme (BACE) inhibitor.
Contract Research & Services > Clinical Trials > News
Advaxis doses first patient with ADXS-NEO cancer immunotherapy
Advaxis has started a phase 1 trial with the dosing of the first patient with ADXS-NEO, an investigational personalized immunotherapy candidate targeting personal neoantigens found by sequencing a patient’s own cancer cells.
Contract Research & Services > Clinical Trials > News
FDA accepts Cellenkos’ IND to begin clinical trial of CK0801 for bone marrow failure syndromes
The US Food and Drug Administration (FDA) has cleared Cellenkos’ investigational new drug (IND) application to proceed with a phase I clinical trial of CK0801, third party cord blood derived regulatory T cells, in patients with bone marrow failure syndrome including aplastic anemia, myelodysplastic syndrome and myelofibrosis.
Contract Research & Services > Clinical Trials > News
Alnylam's Lumasiran yields positive results in phase 1/2 Hyperoxaluria study
Alnylam Pharmaceuticals said that lumasiran, its investigational RNAi therapeutic targeting glycolate oxidase (GO) has yielded positive results from a phase 1/2 study in patients with Primary Hyperoxaluria Type 1 (PH1).
Contract Research & Services > Clinical Trials > News
AbbVie’s upadacitinib succeeds in phase 3 trial in rheumatoid arthritis
AbbVie said that the phase 3 SELECT-EARLY trial evaluating two doses of upadacitinib (15 mg and 30 mg) as monotherapy in the treatment of rheumatoid arthritis met the primary endpoints of ACR50a at week 12 and clinical remissionb at week 24 versus methotrexate (MTX).
Contract Research & Services > Clinical Trials > News
AstraZeneca says Lynparza/abiraterone combo delayed disease progression in mCRPC
By PBR Staff Writer
AstraZeneca has reported that Lynparza (olaparib) in combination with abiraterone succeeded in a phase II trial by delaying disease progression in metastatic castration-resistant prostate cancer (mCRPC) patients.
Contract Research & Services > Clinical Trials > News

PBR Supplier Recommendations

CTL Laboratories - Contract Immune Monitoring and Research
Cellular Technology Limited (CTL), headquartered in Shaker Heights, OH, is a privately held biotechnology company that built its reputation as the global leader in the ELISPOT field over the past two decades by establishing the ELISPOT instrumentation and scientific principles that have helped to define the parameters of ELISPOT research for monitoring of Cell-Mediated Immunity.... Contract Research & Services > Clinical Trials > Suppliers
See more

PBR White Paper Recommendations

Cellular Technology Limited: A multicolor Natural Killer cell-mediated cytotoxicity detection By CTL Laboratories
A multicolor Natural Killer cell-mediated cytotoxicity detection using fluorescence and direct cell imaging.... Contract Research & Services > Clinical Trials > White Papers User vs. Software-Dependent Variability of ELISPOT Counts Obtained from ten Different Laboratories By CTL Laboratories
In ELISPOT assays, cytokine spots produced by antigen-specific T cells show a broad spectrum of sizes and densities over variable background. Therefore, even experienced investigators are likely to come up with different spot counts when subjectively judging the minimal spot size/density to be counted and the maximal spot size for the cut off between singlecell-derived spots vs. those created by cell clusters. This study aims to find out whether statistics-based automated gating can harmonize spot counts obtained in different laboratories.... Contract Research & Services > Clinical Trials > White Papers ELISPOT Assays Provide Reproducible Results Among Different Laboratories for T-cell Immune Monitoring - Even in Hands of ELISPOT's Inexperienced Investigators By CTL Laboratories
Measurements of antibodies in bodily fluids (e.g., by ELISA) have provided robust and reproducible results for decades and such assays have been validated for monitoring of B-cell immunity. In contrast, measuring T-cell immunity has proven to be a challenge due to the need to test live cells in functional assays ex vivo. Several previous efforts looking into the reproducibility of ex vivo T-cell assays between different laboratories, or even within the same laboratory, have provided rather discouraging results.... Contract Research & Services > Clinical Trials > White Papers How Frequently are Predicted Peptides Actually Recognised by CD8 Cells? By CTL Laboratories
Detection of antigen-specific CD8 cells relies on the use of peptides that can bind to HLA-Class I molecules. There is extensive knowledge on individual HLA-alleles’ peptide binding requirements and for many antigens immunogenic peptides have been defined. The 32 individual peptides that comprise the CEF peptide pool represent such well-defined peptide determinants for Cytomegalo, Epstein Barr, and Flu virus. We tested 42 healthy human donors on the accuracy of these peptide predictions.... Contract Research & Services > Clinical Trials > White Papers Four-Colour B Cell ELISPOT Assay for Simultaneous Detection of all Four Human IgG Subclasses By CTL Laboratories
ELISPOT assays are a key research tool for enumerating antigen-specific B cells.... Contract Research & Services > Clinical Trials > White Papers See more
1-15 of 5251 results